BioNTech beruft Annemarie Hanekamp als Chief Commercial Officer in den Vorstand
March 20, 2024 06:00 ET
|
BioNTech SE
Mainz, Deutschland, 20. März 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Annemarie Hanekamp mit Wirkung zum 1. Juli...
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
March 20, 2024 06:00 ET
|
BioNTech SE
Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management...
BNTX DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX
March 11, 2024 13:55 ET
|
The Rosen Law Firm PA
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
BIONTECH SE (NASDAQ: BNTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE
March 11, 2024 08:00 ET
|
Bernstein Liebhard LLP
Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE
BioNTech präsentiert auf der AACR-Jahrestagung 2024 klinische Daten-Updates zu mRNA-basierten und zielgerichteten Onkologie-Kandidaten
March 11, 2024 07:45 ET
|
BioNTech SE
MAINZ, Deutschland, 11. März 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Association for Cancer Research („AACR“), die vom...
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
March 11, 2024 07:45 ET
|
BioNTech SE
MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association...
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX
March 07, 2024 15:09 ET
|
The Rosen Law Firm PA
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
DEADLINE ALERT: Bernstein Liebhard LLP Reminds BioNTech SE Investors of Upcoming Deadline
March 07, 2024 07:30 ET
|
Bernstein Liebhard LLP
DEADLINE ALERT: Bernstein Liebhard LLP Reminds BioNTech SE Investors of Upcoming Deadline
BioNTech gibt geplanten Ruhestand von Sean Marett bekannt
March 07, 2024 06:45 ET
|
BioNTech SE
MAINZ, Deutschland, 7. März, 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech” oder “das Unternehmen”) gab heute bekannt, dass Sean Marett, Chief Business and Commercial Officer, in den Ruhestand gehen und...
BioNTech Announces Planned Retirement of Sean Marett
March 07, 2024 06:45 ET
|
BioNTech SE
Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean Marett, Chief Business and Commercial Officer, will retire as planned...